R&D in the 'age of agile'

Jennifer Jager Posted 12 November 2019

In order to meet the rising customer and stakeholder expectations, R&D companies are focusing more and more on an Agile way of working to speed up the product development process.

Agility is attractive to any company, including pharma companies, because it has the potential to significantly reduce time to market. It requires companies to spend their time on value-added work and promotes fast reallocation of resources based on quicker decision making and engagement.

Within Life Sciences R&D, the introduction of agile principles seems to be in its early stages. The question becomes: "how can companies become more agile to surpass their competition in bringing valuable products to patients?"

Key elements that will make the R&D operating model nimbler require a fundamental change in order to increase productivity.
Those elements include, for example:

  • a revision of R&D strategy to become more Venture Capital-like
  • A mindset, process and governance shift enabling faster decision making through fully leveraging data and analytics to facilitate informed decisions.

Source: McKinsey & Company

Changing these areas in the R&D operating model is not an easy feat considering the inherent complexities of R&D and levels of investment required. However, if Life Science companies want to succeed in staying competitive and delivering value to stakeholders and patients, implementing these agile strategies into their R&D operating model might be taking a step in the right direction. Our experts will be happy to guide you through this process.

Jennifer JaegerProject Manager Life SciencesTweet this

Interested in our expertise in this field?

Please do not hesitate to get in touch with us!

Get in touch